Impact of Chronic Statin Therapy on Postprocedural Contrast-Induced Nephropathy in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention

Journal of Invasive Cardiology

Volumn 27, Issue 11, 2015, Pages 490-496

  Chanin, Jake M ^a   Yang, David C ^a   Haider, Muhammad A ^a   Swaminathan, Rajesh V ^a   Kim, Luke K ^a   Charitakis, Konstantinos ^a   Tanoue, Michael ^a   Minutello, Robert M ^a   Gade, Christopher L ^a   Singh, Harsimran S ^a   Bergman, Geoffrey ^a   Wong, S Chiu ^a   Feldman, Dmitriy N ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Contrast induced nephropathy (CIN); Percutaneous coronary intervention (PCI); Statin

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; CREATININE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IODIXANOL; IOHEXOL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; CONTRAST MEDIUM;

ACUTE HEART FAILURE; AGED; ARTICLE; BLEEDING; CONFIDENCE INTERVAL; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENTING; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; RISK FACTOR; STENT THROMBOSIS; TREATMENT OUTCOME; ADVERSE EFFECTS; CHEMICALLY INDUCED; CLINICAL TRIAL; CORONARY ANGIOGRAPHY; FOLLOW UP; KIDNEY DISEASES; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PREOPERATIVE CARE; PROCEDURES; RETROSPECTIVE STUDY;

AGED; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; MALE; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84946730327     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008;51:1419-1428.
2. Gurm HS, Dixon SR, Smith DE, et al. Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2011;58:907-914.
3. Zhang B-C, Li W-M, Xu Y-W. High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol. 2011;27:851-858.
4. Senoo T, Motohiro M, Kamihata H, et al. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol. 2010;105:624-628.
5. James MT, Ghali WA, Knudtson ML, et al. Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation. 2011;123:409-416.
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
7. Tikkanen MJ, Szarek M, Fayyad R, et al. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J Am Coll Cardiol. 2009;54:2353-2357.
8. Arca M, Gaspardone A. Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events. Drugs. 2007;67(Suppl 1):29-42.
9. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage. J Am Coll Cardiol. 2014;63:71-79.
10. Han Y, Zhu G, Han L, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol. 2014;63:62-70.
11. Li W, Fu X, Wang Y, et al. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology. 2012;122:195-202.
12. Dashti-Khavidaki S, Moghaddas A, Heydari B, Khalili H, Lessan-Pezeshki M, Lessan-Pezeshki M. Statins against drug-induced nephrotoxicity. J Pharm Pharm Sci. 2013;16:588-608.
13. John S, Schneider MP, Delles C, Jacobi J, Schmieder RE. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J. 2005;149:473.
14. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol. 1999;33:234-241.
15. Feldman DN, Minutello RM, Bergman G, Moussa I, Wong SC. Relation of troponin I levels following non-emergent percutaneous coronary intervention to short-and long-term outcomes. Am J Cardiol. 2009;104:1210-1215.
16. Sesso HD, Paffenbarger RS, Lee IM. Comparison of National Death Index and World Wide Web death searches. Am J Epidemiol. 2000;152:107-111.
17. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther. 2003;99:95-112.
18. Quintavalle C, Fiore D, De Micco F, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 2012;126:3008-3016.
19. Patti G, Ricottini E, Nusca A, et al. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial). Am J Cardiol. 2011;108:1-7. Epub 2011 Apr 27.
20. Yoshida S, Kamihata H, Nakamura S, et al. Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency. J Cardiol. 2009;54:192-198.
21. Pappy R, Stavrakis S, Hennebry TA, Abu-Fadel MS. Effect of statin therapy on contrast-induced nephropathy after coronary angiography: a meta-analysis. Int J Cardiol. 2011;151:348-353.
22. Li Y, Liu Y, Fu L, Mei C, Dai B. Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials. 2012;7:e34450
23. Gandhi S, Mosleh W, Abdel-Qadir H, Farkouh ME. Statins and contrast-induced acute kidney injury with coronary angiography: systematic review and meta-analysis. Am J Med. 2014;127:987-1000.
24. Giacoppo D, Capodanno D, Capranzano P, Aruta P, Tamburino C. Meta-analysis of randomized controlled trials of preprocedural statin administration for reducing contrast-induced acute kidney injury in patients undergoing coronary catheterization. Am J Cardiol. 2014;114:541-548.
25. Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005;118:843-849.
26. Jabara R, Gadesam RR, Pendyala LK, et al. Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention. Am J Cardiol. 2009;103:1657-1662.